Watch ABCL. Know when insiders buy.
One email the day a filing lands. Free.
Work order
84
PASS · insiders 75, shorts 92
Insiders, 90 days
+$570K
net buying · 1 buy, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.5BP/E —DIV YIELD —FCF YIELD -3.41%REV TTM $66.2M +101.3%NET INCOME −$164.7MNET CASH $119.9M52W 2.78 – 12.50SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $4M | −76.3% | — | −$62.8M | −$55.4M | — | -0.18 | $25.9M | $2.1M | $23.8M | Aug 5 |
| Q1 2026 · Mar 31 | $8.3M | +96.3% | — | −$57.5M | −$43.2M | — | -0.14 | −$33.5M | $3.8M | −$37.4M | Aug 5 |
| Q4 2025 · Dec 31derived | $44.9M | +788.2% | — | −$28.6M | −$8.9M | — | -0.03 | −$34.7M | $9.8M | −$44.6M | Feb 24 |
| Q3 2025 · Sep 30 | $9M | +37.6% | — | −$76.3M | −$57.1M | — | -0.19 | −$52.6M | $8.9M | −$61.5M | Nov 6 |
| Q2 2025 · Jun 30 | $17.1M | +133.3% | — | −$49.6M | −$34.7M | — | -0.12 | −$32.4M | $13.4M | −$45.8M | Aug 5 |
| Q1 2025 · Mar 31 | $4.2M | −57.5% | — | −$62.7M | −$45.6M | — | -0.15 | −$11.6M | $10.6M | −$22.2M | Aug 5 |
| Q4 2024 · Dec 31derived | $5M | −45.0% | — | −$72.8M | −$34.2M | — | -0.11 | −$8M | $15.6M | −$23.6M | Feb 24 |
| Q3 2024 · Sep 30 | $6.5M | −1.4% | — | −$93.7M | −$51.1M | — | -0.17 | −$28.9M | $18.5M | −$47.4M | Nov 6 |
| Q2 2024 · Jun 30 | $7.3M | — | — | −$93.5M | −$36.9M | — | -0.13 | −$30M | $20.1M | −$50.1M | Nov 6 |
| Q1 2024 · Mar 31 | $10M | — | — | −$54.9M | −$40.6M | — | -0.14 | −$41.7M | $24.1M | −$65.8M | Nov 6 |
| Q4 2023 · Dec 31derived | $9.2M | — | — | −$66.1M | −$47.1M | — | -0.17 | −$19.6M | $14.4M | −$34M | Feb 24 |
| Q3 2023 · Sep 30 | $6.6M | — | — | −$54.9M | −$28.6M | — | -0.10 | −$106K | $20.3M | −$20.4M | Nov 4 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $75.1M | — | −$217.1M | −$146.4M | -194.9% | -0.49 | −$131.3M | $42.8M | −$174.1M | — | — |
| FY2024 · to Dec 31 | $28.8M | — | −$314.8M | −$162.9M | -564.8% | -0.55 | −$108.6M | $78.4M | −$187M | — | — |
| FY2023 · to Dec 31 | $38M | — | −$237.2M | −$146.4M | -385.0% | -0.51 | −$43.9M | $76.9M | −$120.8M | — | — |
| FY2022 · to Dec 31 | $485.4M | — | $216.5M | $158.5M | 32.7% | 0.50 | $277.4M | $70.7M | $206.7M | — | — |
| FY2021 · to Dec 31 | $375.2M | — | $204.4M | $153.5M | 40.9% | 0.48 | $244.6M | $58.5M | $186.1M | — | — |
| FY2020 · to Dec 31 | $233.2M | — | $156M | $118.9M | 51.0% | 0.45 | $22.7M | $9.7M | $13M | — | — |
Every number comes from AbCellera Biologics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.